T1	Participants 14 59	social disability in autism spectrum disorder
T2	Participants 477 569	52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions
T3	Participants 588 689	49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training
